Pluristem Announces Agreement With Japan's PMDA on Design of Final Trial Needed to Apply for Conditional Approval of PLX-PAD

By: via Benzinga
Pluristem Therapeutics Inc. (Nasdaq: PSTI) today announced that it has reached an agreement with Japan's Pharmaceuticals and Medical ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.